Shared PRAME epitopes are T-cell targets in NUT carcinoma
<i>PRAME</i> is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.
Authors
- Christopher Alexander French (ORCID: https://orcid.org/0000-0002-7434-4987)
- Steven Vensko (ORCID: https://orcid.org/0000-0001-9399-5999)
- Jeffrey L. Jensen (ORCID: https://orcid.org/0000-0002-8821-4980)
- Alex Rubinsteyn
- Brandon A. Price (ORCID: https://orcid.org/0000-0002-2478-2081)
- Sara K. Peterson
- Shawn Yu
- Kwangok P. Nickel
- Julie K. Geyer
- Jessica R Alley
- Laura E Herring
- Tomoaki Kinjo
- Randall J Kimple
- Brian Kuhlman
- Jared M Weiss
- Rishi S Kotecha
Institutions
- University of North Carolina at Chapel Hill (US)
- Translational Research Institute (AU)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Curtin University (AU)
- Princess Margaret Hospital for Children (AU)
- University of Wisconsin Carbone Cancer Center (US)
- Tempus Labs (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013539
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00